Document is current

Article History

Received: 8 July 2019

Accepted: 5 January 2020

First Online: 15 January 2020

Ethics approval and consent to participate

: Ethics approval has been obtained for 13 centres (the centres in Lille and Paris are in the process of obtaining approval):Ethics committee Ulm University, approval number 408/17Ethics Committee of the University of Leipzig, approval number 029/18-IkComité Autonómico de Ética de la Investigación de Galicia (Spain), approval number 2017/477Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Area Vasta Nord Ovest (CEAVNO), protocol number 4336 approved 21/12/2017Ethics committee Endocrinology Research Centre, Moscow, Russia, approval number 23 of December 27th, 2017Ethics committee Dokuz Eylul University, Turkey, IRB approval number 2018/22–38Ethics committee “Area Vasta Emilia Centro”, S. Orsola-Malpighi hospital, university of Bologna, approval number 1302/18Medical Ethics Committee Amsterdam University Medical Center, Amsterdam, approved 07/07/2017Ethics committee of the Policlinico Tor Vergata (Rome), approval number 214/18Ethics committee of the Ärztekammer Westfalen-Lippe und Westfälischen Wilhelms-Universität, approval number 2018–527-b-SCyprus National Bioethics Committee, approval number ΕΕΒΚ/ΕΠ/2019/40.Ethics committee- Wales REC 7, REC No. 19/WA/0095, Approved 1/4/19Ethics committee of the Centro Hospitalar Universitário do Porto (CHUP) and the Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, approval number 2019.081 (069-DEFI/070-CE)Comité d’expertise pour les recherches, les études et les évaluations dans le domaine de la santé (CEREES): n° INDS: TPS 33080bis, 06.09.2018

: Not applicable

: The ECLip Registry does not receive any funding from private companies. Some of the authors have however received fees or funding from private companies for work unrelated to the ECLip Registry:J.v.S. has worked as a consultant for Rhythm Pharmaceuticals and Aegerion Pharmaceuticals and received travel funds from Ipsen, Novo Nordisk, and Merck Serono.D.A-V. has worked as an advisor for Bristol-Myers-Squibb, AstraZeneca, and Aegerion Pharmaceuticals.M.W. received personal fees from the Bristol-Myers Squibb, AstraZeneca and the Diabetes Alliance.C.Vi has has received personal fees for consultancy from AstraZeneca and Aegerion Pharmaceuticals, for lectures from Ipsen, Lilly, Viiv Healthcare, Janssen-Cilag, Boehringer-Ingelheim and Merck Serono, for travel from Aegerion Pharmaceuticals, Laboratoires Servier, Novo Nordisk, Orkyn, Sanofi, Vitalaire, Air Products, Boehringer-Ingelheim, Gilead, Novartis and Bristol-Myers Squibb, and has received institutional research fundings from Aegerion Pharmaceuticals, Pierre Fabre Médicament, Laboratoires Servier and Roche Diagnostics.F. S has worked as a consultant, participated in studies and/or received travel funds from the following companies that are involved with lipodistropy and/or diabetes: AstraZeneca, Aegerion, Pharmaceuticals, Novo Nordisk, Bruno Pharma.M.C. V received non-financial support from Novartis, Aegerion Pharmaceuticials, Ipsen, Shire, HRA Pharma and personal fees from Sanofi.P. S. received fees as a consultant by Aegerion Pharmaceuticals, Novo Nordisk, Bruno Pharma and AstraZeneca.A. G. received fees as a consultant by Aegerion Pharmaceuticals.B.A. has attended Advisory Board Meetings organized by Aegerion Pharmaceuticals and Regeneron Pharmaceuticals and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis.E.S.-S. has received a compensation from Aegerion Pharmaceuticals for her work as Consultant in a Portuguese Lipodystrophy Expert Meeting.E.S. has received fees for her work on an advisory board for Regeneron and for AstraZeneca.K.M. has received fees for consulting Aegerion Pharmaceuticals.G.C. has received fees for consulting AstraZeneca, Aegerion Pharmaceuticals and Rhythm Pharmaceuticals.C.Va. has has received personal fees for consultancy from AstraZeneca, Aegerion Pharmaceuticals, MSD, for lectures from Novo Nordisk, Sanofi, for travel from Aegerion Pharmaceuticals, Laboratoires Servier, Lilly, LVL, Novo Nordisk, Orkyn, Sanofi, Vitalaire, Novartis and has received institutional research fundings from Aegerion Pharmaceuticals, Sanofi.C.A. received honoraria as a speaker from Aegerion Pharmaceuticals.